ArticleBMC microbiology2026
Domestic pig skin peptides: targeted starvation therapy for gram-positive bacteria MRSA through ABC transporters.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antimicrobial peptides (AMPs), which were conserved constituents of the innate immune system, exhibit antimicrobial properties similar to those of traditional antibiotics and have a low potential for the development of resistance. Thus, they were showing a great capacity for application. This study performed screening of twelve candidate antimicrobial peptides by means of pig skin enzymatic hydrolysis and activity prediction. The synthesis of these peptides was undertaken using Fmoc solid phase synthesis and purified via HPLC than 95%. The Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus (SA) and Escherichia coli (E. coli) were selected to evaluate antibacterial activity in vitro. The results indicated that peptide P5 exhibited the most significant inhibitory effect on MRSA and SA, with an inhibition rate of 91.83%. Furthermore, its antibacterial activity against MRSA and SA was found to be stronger than that against E. coli, demonstrating a dose-dependent relationship. Growth curve analysis revealed that P5 completely inhibited the growth of MRSA within 16 h at 3 mg/mL. Cytotoxicity was assessed using the CCK-8 assay and live/dead cell staining. The survival rates of both L929 and MDCK cells exceeded 87%, indicating good biocompatibility. Transcriptome sequencing (RNA-seq) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses demonstrated that treatment with the P5 was associated with significant transcriptional changes in MRSA. The differentially expressed genes were enriched in the ABC transporter pathway, as well as pathways related to arginine biosynthesis and metabolism, histidine metabolism, and quorum sensing. These findings suggest a potential link between P5 and these pathways, thereby providing a foundation for future mechanistic studies. In conclusion, the porcine skin-derived antimicrobial peptide P5 exhibited significant antimicrobial activity, low cytotoxicity, and a mechanism of action that was distinct from traditional antibiotics, thereby demonstrating promising potential for clinical translation in the fight against drug-resistant bacterial infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.